Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination

L. Calzetta (Rome, Italy), M. Matera (Naples, Italy), J. Ora (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), P. Rogliani (Rome, Italy)

Source: International Congress 2019 – Advances in asthma pharmacology
Session: Advances in asthma pharmacology
Session type: Poster Discussion
Number: 3873
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Calzetta (Rome, Italy), M. Matera (Naples, Italy), J. Ora (Rome, Italy), F. Facciolo (Rome, Italy), M. Cazzola (Rome, Italy), P. Rogliani (Rome, Italy). Mechanisms leading to the bronchorelaxant synergy of ICS/LABA/LAMA combination. 3873

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity
Source: Eur Respir J, 59 (3) 2004306; 10.1183/13993003.04306-2020
Year: 2022



Understanding the mechanisms of TKIs: the cycle of inhibition and resistance
Source: International Congress 2016 – The future of tyrosin kinase inhibitors
Year: 2016


Dual mechanism of action of T2 inhibitor therapies in virally induced exacerbations of asthma: evidence for a beneficial counter-regulation
Source: Eur Respir J, 54 (1) 1802390; 10.1183/13993003.02390-2018
Year: 2019



The loss of pulmonary barrier function as a result of application of anticancer agents paclitaxel, 2-methoxyestradiol, and their combination
Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis
Year: 2010


Anti-inflammatory function of tiotropium mediated by suppression of acetylcholine-induced release of chemotactic activity
Source: Eur Respir J 2004; 24: Suppl. 48, 318s
Year: 2004

Role of altered immune response in CF and implication for antiinflammatory therapies
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012


Novel inhibitory effect on 5-lipoxygenase activity by montelukast. Evidence for a noncompetitive mode of action
Source: Eur Respir J 2004; 24: Suppl. 48, 96s
Year: 2004

Mechanisms of vascular endothelial cell injury in response to intermittent and continuous hypoxia exposure and protective effects of anti-inflammatory and anti-oxidant agents
Source: International Congress 2019 – Novel methods, diagnostics and biomarkers in chronic lung diseases
Year: 2019

Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019


Mechanisms leading to the bronchoprotective effects of N-Acetylcysteine in human bronchi stimulated by lipopolysaccharide
Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control
Year: 2018




Synergistic inhibition of oxidative burst in human eosinophils by combination treatment with formoterol and budesonide
Source: Eur Respir J 2001; 18: Suppl. 33, 48s
Year: 2001

TNFα-induced glucocorticoid resistance: Effect of steroidal and non-steroidal GR agonists, formoterol and inhibition of inflammatory signalling
Source: Annual Congress 2012 - Molecular biology of pro- and anti-inflammatory responses in the lung
Year: 2012

cPLA2alpha inhibitor ASB14780 suppresses airway MMP-9 production and improves respiratory function in cigarette-smoke induced model
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014


Mechanisms underlying nicotine dependency
Source: International Congress 2014 – End of the tobacco epidemic: from individual to societal strategies
Year: 2014



A combination of thyme and ivy exerts potent anti-inflammatory and mucus-normalizing activity in vivo and inhibits 5-LO and PDE4
Source: International Congress 2014 – Animal models in respiratory drug development
Year: 2014

Synergistic action of formoterol on budesonide-generated decrease of proteoglycan production by activated lung fibroblasts is mediated via β-adrenergic receptor and is dependent on glucocorticoid receptor
Source: Eur Respir J 2004; 24: Suppl. 48, 345s
Year: 2004

The combination of budesonide and formoterol exerts more rapid and enhanced anti-inflammatory effects than either drug alone in rat lungs in vivo
Source: Eur Respir J 2004; 24: Suppl. 48, 344s
Year: 2004

Topically applied budesonide and formoterol in combination inhibit rat lung oedema in a synergistic way but counteract the slight systemic effects of each drug alone on body weight gain
Source: Eur Respir J 2002; 20: Suppl. 38, 387s
Year: 2002

Synergistic effects by combination of tiotropium with olodaterol result from cross talk between muscarinic and β2-adrenergic receptors via allosteric modulation
Source: International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Year: 2016